Alembic Pharma stock rose 10.92% today after a major win from the US Food and Drug Administration (USFDA). The approval is for Doxorubicin Hydrochloride Liposome Injection, a key cancer treatment drug.
This drug is the generic version of Doxil Liposome Injection, developed by Baxter Healthcare. It is used to treat ovarian cancer, AIDS-related Kaposi’s sarcoma, and multiple myeloma. The drug comes in single-dose vials, which are commonly used in hospitals for cancer patients.
A $29 Million Market Opens Up
According to IQVIA, the US market for this drug was worth $29 million in the 12 months ending March 2025. That’s a big opportunity for Alembic Pharma, which is now officially allowed to sell this drug in the US.
This marks Alembic’s 224th ANDA (Abbreviated New Drug Application) approval from the USFDA—out of which 201 are final approvals. That’s a big achievement for an Indian pharmaceutical company, and a strong signal of global trust in its quality.
Alembic’s Global Growth Continues
Alembic Pharmaceuticals is not new to the global market. It has research and manufacturing facilities approved by major regulators like the USFDA and EU authorities. It makes and sells generic drugs worldwide, building a strong presence in developed countries.
This USFDA approval is expected to boost Alembic’s global sales and reputation, especially in the field of oncology (cancer treatment).
Mixed Financial Results, But Strong Pipeline
Interestingly, Alembic reported a 12% drop in net profit for Q4 FY25, down to ₹156.89 crore, even though net sales went up 16.7% to ₹1,769.64 crore. That said, new drug approvals like this one could help the company bounce back stronger in the next quarters.
What This Means for Indian Pharma
Alembic’s success reflects how Indian pharma is not just about making cheaper drugs. It’s also about innovation, global standards, and winning trust in the world’s toughest markets. While Western pharma giants face regulatory delays and high costs, Indian companies like Alembic are moving fast and smart.
Alembic Pharma is clearly on the move. The 10.92% stock surge isn’t just about one drug—it’s about what the company is building: a global pharma force with Indian roots.
Also Read Torrent Pharma to Acquire Controlling Stake in JB Chemicals for ₹25,689 Cr
